Tempest Therapeutics is eyeing a strategic partner to continue amezalpat’s development amid ‘unavailable capital markets'.

Unable to secure additional financing amid a stormy market, Tempest Therapeutics has put a call out for partners as it seeks ...

According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global ...

Sunshine Biopharma's K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 ...

The complete response letter, issued by the FDA, does not identify what deficiencies regulators found in ...

Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC) • Announced Agreement with Roche to Support Advancement ...

Imfinzi isn’t approved to treat HCC, either alone or in combination with other drugs, and the new data suggests route for AZ to target this form of cancer. The principal investigator in Study 22 ...

Human hepatocellular carcinoma (HCC) is the third leading cause of cancer ... Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and 13 additional drugs ...

HealthDay News — For patients with chronic liver disease, statin use is associated with a reduced risk for hepatocellular carcinoma (HCC) and hepatic decompensation, according to a study published ...